Biologics for Asthma Underused in Multinational Survey

Why It Matters

The low adoption of asthma biologics limits patients’ ability to achieve better disease control and drives continued reliance on oral steroids, raising both health risks and overall healthcare costs.

Key Takeaways

• Only 11% eligible patients use biologics.
• Schedule difficulty cited by 37% of discontinuers.
• Injection/device issues affect over a third.
• Cost not primary barrier in US market.
• Lower biologic use correlates with higher prednisone use.

Pulse Analysis

The GAAPP Time Clock Survey, presented at the AAAAI meeting, highlights a stark gap between clinical guidelines and real‑world practice for severe asthma. Despite decades of biologic development and clear eligibility criteria—GINA step 3 or higher—just over one in ten patients are on these disease‑modifying agents. This underutilization is not confined to a single market; the study spanned seven countries, revealing a consistent pattern of low uptake that undermines the promise of personalized asthma care.

Patient‑centred barriers dominate the conversation. Over a third of respondents who stopped biologics cited scheduling conflicts, indicating that the frequency and logistics of administration remain a friction point. While a modest majority expressed a preference for six‑month injections over monthly ones, the complexity of devices and needle anxiety also deter adherence. Notably, cost, often presumed to be the primary obstacle, ranked lower in the United States thanks to robust manufacturer access programs, though it still affected a quarter of discontinuers. These insights suggest that simplifying delivery mechanisms and aligning dosing schedules with routine healthcare visits could markedly improve persistence.

The clinical repercussions are evident: regions with the lowest biologic penetration reported higher oral prednisone use, exposing patients to steroid‑related side effects and inflating long‑term treatment costs. Health systems stand to benefit from strategies that boost biologic adoption—such as integrated care pathways, patient education, and streamlined reimbursement—to reduce steroid dependence. Looking ahead, extending this research to pediatric cohorts will be crucial, as children may face distinct adherence challenges and could reap even greater benefits from early biologic intervention.